Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
A study for patients with lupus nephritis, using an investigational treatment design with rituximab, cyclophosphamide, and solumedrol
Sponsor: National Institute of Allergy and Infectious Disea
Enrolling: Male and Female Patients
Study Length: 96 Weeks
Clinic Visits: 20
IRB Number: AAAP5708
U.S. Govt. ID: NCT02260934
Contact: Anca Askanase MD MPH: (212) 305-0856 / ada20@cumc.columbia.edu
Additional Study Information: In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.
This study is closed
Investigator
Anca Askanase, MD, MPH
Do You Qualify?
Are you diagnosed with Systemic Lupus Erythematosus (SLE)? Yes No
Do you have active proliferative lupus nephritis? Yes No
Are you willing to use an FDA-approved form of birth control? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Anca Askanase MD MPH
ada20@cumc.columbia.edu
(212) 305-0856
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE